Kaare Meier

Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

Standard

Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes. / Poulsen, Dennis Møgeltoft; Sørensen, Jens Christian Hedemann; Blichfeldt-Eckhardt, Morten Rune; Gulisano, Helga Angela; Meier, Kaare.

2020. Abstract from 23th Annual Meeting (North American Neuromodulation Society), Las Vegas, United States.

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

Harvard

Poulsen, DM, Sørensen, JCH, Blichfeldt-Eckhardt, MR, Gulisano, HA & Meier, K 2020, 'Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes', 23th Annual Meeting (North American Neuromodulation Society), Las Vegas, United States, 23/01/2020 - 26/01/2020.

APA

Poulsen, D. M., Sørensen, J. C. H., Blichfeldt-Eckhardt, M. R., Gulisano, H. A., & Meier, K. (2020). Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes. Abstract from 23th Annual Meeting (North American Neuromodulation Society), Las Vegas, United States.

CBE

Poulsen DM, Sørensen JCH, Blichfeldt-Eckhardt MR, Gulisano HA, Meier K. 2020. Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes. Abstract from 23th Annual Meeting (North American Neuromodulation Society), Las Vegas, United States.

MLA

Poulsen, Dennis Møgeltoft et al. Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes. 23th Annual Meeting (North American Neuromodulation Society), 23 Jan 2020, Las Vegas, United States, Conference abstract for conference, 2020.

Vancouver

Poulsen DM, Sørensen JCH, Blichfeldt-Eckhardt MR, Gulisano HA, Meier K. Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes. 2020. Abstract from 23th Annual Meeting (North American Neuromodulation Society), Las Vegas, United States.

Author

Poulsen, Dennis Møgeltoft ; Sørensen, Jens Christian Hedemann ; Blichfeldt-Eckhardt, Morten Rune ; Gulisano, Helga Angela ; Meier, Kaare. / Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes. Abstract from 23th Annual Meeting (North American Neuromodulation Society), Las Vegas, United States.

Bibtex

@conference{3b190dfb70f7448f8fa4f1edb200d96a,
title = "Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes",
abstract = "Introduction The clinical outcome of spinal cord stimulation (SCS) shows very large individual variation: Some patients experience almost complete pain relief, while others have no beneficial effect at all and ultimately undergo explantation of the SCS device. Therefore, the implanter needs to rely on different assessment tools when evaluating SCS candidates. One such tool is the Pain Catastrophizing Scale (PCS) being a 13-item psychological evaluation instrument used to measure the level of catastrophic thinking in relation to pain. The scale yields a score from 0-52; 0 = no catastrophic thinking, 52 = highest possible level of catastrophic thinking. Previous studies investigating the use of PCS scores as a predictor of SCS outcomes showed conflicting results. The aim of this cohort study was to investigate whether baseline PCS scores in SCS patients could predict: 1) Latest rating on Patients{\textquoteright} Global Impression of Change Scale5 (PGIC) and 2) Risk of undergoing permanent explantation of the SCS device. MethodsWe used data from the Neurizon Neuromodulation Database containing detailed records of patients implanted with a SCS device at either Aarhus, Odense, or Aalborg University Hospitals, Denmark. Patient follow-up was performed approximately every six months and included the PGIC rating, explantations of SCS devices were continuously being registered in the database. Patients were included if they had a baseline PCS score (obtained prior to implantation) and a minimum follow-up of six months. Included patients were grouped by latest PGIC-rating and subsequently by current treatment status (active stimulation /permanently explanted). A one-way ANOVA was used to evaluate the association between baseline PCS scores and latest PGIC rating, while the relation between baseline PCS scores and current treatment status was assessed using an exact T-test. Results A total of 249 patients we included: 212 had a follow-up PGIC rating, 41 underwent permanent explantation of their SCS device. Mean baseline PCS score of included patients was 30.4, [29.0, 31.7]. No difference in mean baseline PCS score was found between PGIC groups (p-value = 0.15). Mean baseline PCS scores between groups of treatment status did not differ (Diff = -0.3, [-3.9, 3.3], p-value = 0.87). Follow-up ranged from 0.5 - 8 years (median = 3.0 years) and was not associated with treatment outcomes. Conclusion Baseline PCS scores failed to predict both latest PGIC rating and risk of undergoing permanent explantation of the SCS device. Our findings do not provide any support for withholding SCS therapy in patients with a high level of pain catastrophizing. ",
author = "Poulsen, {Dennis M{\o}geltoft} and S{\o}rensen, {Jens Christian Hedemann} and Blichfeldt-Eckhardt, {Morten Rune} and Gulisano, {Helga Angela} and Kaare Meier",
year = "2020",
month = jan,
language = "Dansk",
note = "23th Annual Meeting (North American Neuromodulation Society), NANS 2020 ; Conference date: 23-01-2020 Through 26-01-2020",
url = "https://conference.neuromodulation.org/item/874-2020-annual-meeting-attendee-information",

}

RIS

TY - ABST

T1 - Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes

AU - Poulsen, Dennis Møgeltoft

AU - Sørensen, Jens Christian Hedemann

AU - Blichfeldt-Eckhardt, Morten Rune

AU - Gulisano, Helga Angela

AU - Meier, Kaare

PY - 2020/1

Y1 - 2020/1

N2 - Introduction The clinical outcome of spinal cord stimulation (SCS) shows very large individual variation: Some patients experience almost complete pain relief, while others have no beneficial effect at all and ultimately undergo explantation of the SCS device. Therefore, the implanter needs to rely on different assessment tools when evaluating SCS candidates. One such tool is the Pain Catastrophizing Scale (PCS) being a 13-item psychological evaluation instrument used to measure the level of catastrophic thinking in relation to pain. The scale yields a score from 0-52; 0 = no catastrophic thinking, 52 = highest possible level of catastrophic thinking. Previous studies investigating the use of PCS scores as a predictor of SCS outcomes showed conflicting results. The aim of this cohort study was to investigate whether baseline PCS scores in SCS patients could predict: 1) Latest rating on Patients’ Global Impression of Change Scale5 (PGIC) and 2) Risk of undergoing permanent explantation of the SCS device. MethodsWe used data from the Neurizon Neuromodulation Database containing detailed records of patients implanted with a SCS device at either Aarhus, Odense, or Aalborg University Hospitals, Denmark. Patient follow-up was performed approximately every six months and included the PGIC rating, explantations of SCS devices were continuously being registered in the database. Patients were included if they had a baseline PCS score (obtained prior to implantation) and a minimum follow-up of six months. Included patients were grouped by latest PGIC-rating and subsequently by current treatment status (active stimulation /permanently explanted). A one-way ANOVA was used to evaluate the association between baseline PCS scores and latest PGIC rating, while the relation between baseline PCS scores and current treatment status was assessed using an exact T-test. Results A total of 249 patients we included: 212 had a follow-up PGIC rating, 41 underwent permanent explantation of their SCS device. Mean baseline PCS score of included patients was 30.4, [29.0, 31.7]. No difference in mean baseline PCS score was found between PGIC groups (p-value = 0.15). Mean baseline PCS scores between groups of treatment status did not differ (Diff = -0.3, [-3.9, 3.3], p-value = 0.87). Follow-up ranged from 0.5 - 8 years (median = 3.0 years) and was not associated with treatment outcomes. Conclusion Baseline PCS scores failed to predict both latest PGIC rating and risk of undergoing permanent explantation of the SCS device. Our findings do not provide any support for withholding SCS therapy in patients with a high level of pain catastrophizing.

AB - Introduction The clinical outcome of spinal cord stimulation (SCS) shows very large individual variation: Some patients experience almost complete pain relief, while others have no beneficial effect at all and ultimately undergo explantation of the SCS device. Therefore, the implanter needs to rely on different assessment tools when evaluating SCS candidates. One such tool is the Pain Catastrophizing Scale (PCS) being a 13-item psychological evaluation instrument used to measure the level of catastrophic thinking in relation to pain. The scale yields a score from 0-52; 0 = no catastrophic thinking, 52 = highest possible level of catastrophic thinking. Previous studies investigating the use of PCS scores as a predictor of SCS outcomes showed conflicting results. The aim of this cohort study was to investigate whether baseline PCS scores in SCS patients could predict: 1) Latest rating on Patients’ Global Impression of Change Scale5 (PGIC) and 2) Risk of undergoing permanent explantation of the SCS device. MethodsWe used data from the Neurizon Neuromodulation Database containing detailed records of patients implanted with a SCS device at either Aarhus, Odense, or Aalborg University Hospitals, Denmark. Patient follow-up was performed approximately every six months and included the PGIC rating, explantations of SCS devices were continuously being registered in the database. Patients were included if they had a baseline PCS score (obtained prior to implantation) and a minimum follow-up of six months. Included patients were grouped by latest PGIC-rating and subsequently by current treatment status (active stimulation /permanently explanted). A one-way ANOVA was used to evaluate the association between baseline PCS scores and latest PGIC rating, while the relation between baseline PCS scores and current treatment status was assessed using an exact T-test. Results A total of 249 patients we included: 212 had a follow-up PGIC rating, 41 underwent permanent explantation of their SCS device. Mean baseline PCS score of included patients was 30.4, [29.0, 31.7]. No difference in mean baseline PCS score was found between PGIC groups (p-value = 0.15). Mean baseline PCS scores between groups of treatment status did not differ (Diff = -0.3, [-3.9, 3.3], p-value = 0.87). Follow-up ranged from 0.5 - 8 years (median = 3.0 years) and was not associated with treatment outcomes. Conclusion Baseline PCS scores failed to predict both latest PGIC rating and risk of undergoing permanent explantation of the SCS device. Our findings do not provide any support for withholding SCS therapy in patients with a high level of pain catastrophizing.

M3 - Konferenceabstrakt til konference

T2 - 23th Annual Meeting (North American Neuromodulation Society)

Y2 - 23 January 2020 through 26 January 2020

ER -